The GLUT-1 deficiency is a metabolic disorder caused by a defect in glucose transport across the blood-brain barrier as a result of a defect in the glucose-transport protein. Patients present with epileptic seizures, delayed development, ataxia and hypotonia, and in many cases acquired microcephaly. In most patients, treatment with a ketogenic diet proved to be successful in controlling the epilepsy. We report a 9-year-old boy with retardation and ataxia, but without epilepsy, caused by GLUT-1 deficiency, proven biochemically and by DNA analysis. Treatment with a medium-chain triglyceride ketogenic diet had a beneficial effect.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1023/a:1025999914822 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Micronutrients intake in patients with refractory epilepsy with ketogenic diet treatment].
Andes Pediatr
October 2024
Facultad de Medicina, Departamento de Gastroenterología y Nutrición Pediátrica, Pontificia Universidad Católica de Chile, Santiago, Chile.
Unlabelled: The Ketogenic Diet (KD) is a non-pharmacological strategy for drug-resistant epilepsy (DRE) and inborn errors of metabolism (Glut-1 deficiency) management. KD is characterized by being restrictive, affecting micronutrient intake. There are different modalities of KD in which food intake and nutritional deficiencies vary.
View Article and Find Full Text PDFThioredoxin-interacting protein (TXNIP) inhibition promotes retinal ganglion cell survival and facilitates M1-like microglial transformation via the PI3K/Akt pathway in glaucoma.
Mol Med
December 2024
Department of Ophthalmology, Ruijin Hospital Affiliated Medical School, Shanghai Jiaotong University, 197 Ruijin er Road, Shanghai, 200025, China.
Background: Glaucoma is a group of heterogeneous neurodegenerative diseases with abnormal energy metabolism and imbalanced neuroinflammation in the retina. Thioredoxin-interacting protein (TXNIP) is involved in glucose and lipid metabolism, and associated with oxidative stress and inflammation, however, not known whether to be involved in glaucoma neuropathy and its underlying mechanisms.
Methods: To establish the chronic ocular hypertension (COH) mice model.
Intrinsic ADRB2 inhibition improves CAR-T cell therapy efficacy against prostate cancer.
Mol Ther
October 2024
Shanghai Key Laboratory of Regulatory Biology, School of Life Sciences, East China Normal University, Shanghai 200241, China. Electronic address:
Chimeric antigen receptor (CAR)-T cell therapy has shown limited success in patients with solid tumors. Recent in vitro and in vivo data have shown that adrenoceptor beta-2 (ADRB2) is a novel checkpoint receptor that inhibits T cell-mediated anti-tumor responses. To inhibit ADRB2-mediated inhibitory signaling, we downregulated ADRB2 in CAR-T (shβ-CAR-T) cells via RNA interference, assessed different parameters, and compared them with conventional second-generation CAR-T cells.
View Article and Find Full Text PDF[Epilepsy and inborn errors of metabolism].
Rev Neurol
September 2024
Hospital Universitario Miguel Servet, Zaragoza, España.
Article Synopsis
- - Epilepsy frequently occurs in metabolic disorders, showing varied severity and treatment response, highlighting the importance of understanding its characteristics in these conditions.
- - A study reviewed cases of epilepsy linked to different metabolic diseases, revealing that two-thirds of molybdenum cofactor deficiency cases had neonatal epileptic encephalopathy, while other conditions displayed diverse patterns of incidence and treatment efficacy.
- - Accurate diagnosis of metabolic epilepsy relies on clinical indicators such as age of onset and treatment resistance; further research is needed for early biomarkers and effective targeted therapies despite the rising utility of genetic testing.
Dietary management and access to treatment for patients with glucose deficiency syndrome type 1: an overview review with focus on the European regulatory framework.
Eur J Clin Nutr
December 2024
School of Pharmacy, University of Camerino, Camerino, Italy.
Background: Glut-1 deficiency Syndrome (GLUT-1 DS) is a rare disease caused by a mutation in the SLC2A1 gene that codes for the glucose transporter protein GLUT-1 DS. Currently, there is no indicated drug therapy for this condition and ketogenic diet (KD) is the most effective remedy to treat it.
Objective: The objective of this study was to review the published literature that evaluated the effectiveness of KD in the dietary management of GLUT-1 DS syndrome, describing the state-of-the-art the treatment pathway for patients with GLUT-1 DS syndrome in light of the current European regulatory framework within the National Health Services.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!